<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">research-focus</journal-id>
      <journal-title-group>
        <journal-title>Research Focus International Scientific Journal</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Research Focus</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub" publication-format="electronic">2181-3833</issn>
      <publisher>
        <publisher-name>Ilm-fan va innovatsiyalar akademiyasi</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.66073/researchfocus.v3i1.764</article-id>
      <article-id pub-id-type="other" assigning-authority="relibrary.uz">REL-A-012378</article-id>
      <article-categories>
        <subj-group subj-group-type="oak">
          <subject>14.00.00</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">FAILURE OF THE HEART DETERMINATION PROTEOMIC PROFILING RELATED TO PATIENTS WHO ARE ELDERLY</article-title>
        <trans-title-group xml:lang="ru">
          <trans-title>ПРОТЕОМНОЕ ПРОФИЛИРОВАНИЕ ДЛЯ ОПРЕДЕЛЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У ПОЖИЛЫХ ПАЦИЕНТОВ</trans-title>
        </trans-title-group>
        <trans-title-group xml:lang="uz">
          <trans-title>KEKSA BEMORLARDA YURAK YETISHMOVCHILIGINI ANIQLASHGA OID PROTEOMIK PROFILLASH</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group content-type="author">
        <contrib contrib-type="author">
          <string-name>Yuldashev Soatboy Jiyanboevich</string-name>
          <aff>Candidate of Medical Sciences, Associate Professor, Head of Department</aff>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Imran Aslam</string-name>
          <aff>Ph.D, Department of Pharmacology</aff>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Jiyanboyev Nodirbek Soatboyevich</string-name>
          <aff>5th year student of the Faculty of Medicine of the University of Health Sciences, Bukhara</aff>
        </contrib>
      </contrib-group>
      <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2024-02-05">
        <day>05</day>
        <month>02</month>
        <year>2024</year>
      </pub-date>
      <pub-date date-type="collection">
        <year>2024</year>
      </pub-date>
      <volume>3</volume>
      <issue>1</issue>
      <fpage>198</fpage>
      <lpage>203</lpage>
      <permissions>
        <license xlink:href="https://creativecommons.org/licenses/by/4.0">
          <ali:license_ref>https://creativecommons.org/licenses/by/4.0</ali:license_ref>
          <license-p>This work is licensed under a Creative Commons Attribution 4.0 International License.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="https://relibrary.uz/REL-A-012378/"/>
      <abstract xml:lang="en">
        <p>Objective</p>
        <p>These eighty proteins have been identified to be connected with cardiovascular pathology in the past, and the purpose of this study paper is employing proteomic profiling of these proteins in order to discover new risk factors for heart failure or heart failure in general.</p>
        <p>Materials and Methods</p>
        <p>Analyses of the proximity extension (Proteomic profiling) has been performed in two different communities with varying cohorts in the elderly at the baseline in the absence of cardiac failure. The prospective of the research were Prospective Investigation of the Vasculature (PIV) and Longitudinal Study of Adult Men (LSAM) having respective values (80 events, median age = 70.2 years, n = 901) and (90 events, median age = 77.8 years, n = 685). Incident of heart failure was associated with 29 proteins as observed in PIV with adjusted sex and age. Corrections were made after multiple tests. In LSAM there were 18 proteins associated with heart failure. High level of 9 proteins were related to the incident of heart failure among both the cohorts. There were additional modifications made to the established risk variables. There was a deficit in the left ventricular systolic function that was found to be associated with the presence of growth differentiation factor 15 (GDF-15), urokinase-type plasminogen activator surface receptor (U-PAR), matrix metalloproteinase-12 (MMP-12), tumour necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2), spondin-1 (SPON1), and follistatin (FS). This was discovered through echocardiographic monitoring. Each and every one of the P values was lower than 0.02.</p>
        <p>Results</p>
        <p>The final characteristics of PIV included median age of 70 years among a total of 901 participants. In LSAM the characteristic showed median age of 78 years among 685 participants. During follow-up among PIV the age range was 0.1-10.9 years with a median of 10 years, 80 hospitalizations due to heart failure with a heart failure rate of 0.96 among 100 persons. There were 90 hospitalisations for heart failure among LSAM, the age range was 0.2-10.9 years with a median of 8 years, and the heart failure rate was 1.83 per 100 people. False discovery rate among PIV was 5% with the association of 29 proteins after adjusted sex and age. Among LSAM the association of 18 proteins was nominal for the incident of heart failure.</p>
        <p>Conclusion</p>
        <p>Several novel associations for the involvement of proteins in fibrinolysis, apoptosis, inflammation, matrix remodeling and heart failure were identified through Proteomic profiling in the research study among elderly. The outcomes of this research also correspond to other investigations that studied underlying clinical utilities and mechanisms.</p>
      </abstract>
      <trans-abstract xml:lang="ru">
        <p>Цель. Эти восемьдесят белков ранее были определены как связанные с сердечно-сосудистой патологией, и цель настоящей работы состоит в применении протеомного профилирования этих белков для выявления новых факторов риска сердечной недостаточности или сердечной недостаточности в целом. Материалы и методы. Анализ методом расширения близости (протеомное профилирование) был выполнен в двух различных сообществах с разными когортами пожилых лиц на исходном уровне при отсутствии сердечной недостаточности. Проспективными исследованиями были Проспективное исследование сосудистой системы (PIV) и Лонгитюдное исследование взрослых мужчин (LSAM) с соответствующими значениями (80 событий, медиана возраста = 70,2 года, n = 901) и (90 событий, медиана возраста = 77,8 года, n = 685). Возникновение сердечной недостаточности было связано с 29 белками, как это наблюдалось в PIV с поправкой на пол и возраст. Поправки были внесены после множественных тестов. В LSAM с сердечной недостаточностью были связаны 18 белков. Высокий уровень 9 белков был связан с возникновением сердечной недостаточности в обеих когортах. Были внесены дополнительные поправки на установленные факторы риска. Обнаружен дефицит систолической функции левого желудочка, который оказался связан с наличием фактора дифференцировки роста 15 (GDF-15), поверхностного рецептора активатора плазминогена урокиназного типа (U-PAR), матриксной металлопротеиназы-12 (MMP-12), рецептора 2 лиганда, индуцирующего апоптоз и связанного с фактором некроза опухоли (TRAIL-R2), спондина-1 (SPON1) и фоллистатина (FS). Это было выявлено посредством эхокардиографического мониторинга. Все без исключения значения P были ниже 0,02. Результаты. Итоговые характеристики PIV включали медиану возраста 70 лет среди в общей сложности 901 участника. В LSAM характеристика показала медиану возраста 78 лет среди 685 участников. В период наблюдения в PIV возрастной диапазон составил 0,1-10,9 года с медианой 10 лет, 80 госпитализаций по поводу сердечной недостаточности при частоте сердечной недостаточности 0,96 на 100 человек. В LSAM было 90 госпитализаций по поводу сердечной недостаточности, диапазон составил 0,2-10,9 года с медианой 8 лет, а частота сердечной недостаточности составила 1,83 на 100 человек. Частота ложных открытий в PIV составила 5 % при связи 29 белков после поправки на пол и возраст. В LSAM связь 18 белков с возникновением сердечной недостаточности была номинальной. Заключение. Посредством протеомного профилирования в данном исследовании среди пожилых лиц было выявлено несколько новых связей, указывающих на участие белков в фибринолизе, апоптозе, воспалении, ремоделировании матрикса и сердечной недостаточности. Результаты этого исследования также соответствуют другим работам, изучавшим лежащие в основе механизмы и клиническую применимость.</p>
      </trans-abstract>
      <trans-abstract xml:lang="uz">
        <p>Maqsad. Ushbu sakson oqsil ilgari yurak-qon tomir patologiyasi bilan bog‘liq deb aniqlangan bo‘lib, ushbu tadqiqot ishining maqsadi yurak yetishmovchiligi yoki umuman yurak yetishmovchiligining yangi xavf omillarini topish uchun mazkur oqsillarni proteomik profillashdan foydalanishdir. Materiallar va usullar. Yaqinlikni kengaytirish tahlili (proteomik profillash) yurak yetishmovchiligi bo‘lmagan holatda boshlang‘ich bosqichda keksa yoshdagi turli kogortalarga ega ikki xil jamoada o‘tkazildi. Prospektiv tadqiqotlar sifatida Qon tomir tizimini prospektiv o‘rganish (PIV) va Katta yoshli erkaklarni longitudinal o‘rganish (LSAM) tanlangan bo‘lib, ularning mos qiymatlari (80 hodisa, yoshning medianasi = 70,2 yil, n = 901) va (90 hodisa, yoshning medianasi = 77,8 yil, n = 685) ni tashkil etdi. PIV da jins va yoshga tuzatish kiritilgan holda kuzatilganidek, yurak yetishmovchiligining yuzaga kelishi 29 ta oqsil bilan bog‘liq edi. Tuzatishlar ko‘p sonli testlardan so‘ng kiritildi. LSAM da yurak yetishmovchiligi bilan bog‘liq 18 ta oqsil aniqlandi. Har ikkala kogortada 9 ta oqsilning yuqori darajasi yurak yetishmovchiligining yuzaga kelishi bilan bog‘liq bo‘ldi. Belgilangan xavf omillariga qo‘shimcha tuzatishlar kiritildi. Chap qorincha sistolik funksiyasining yetishmovchiligi aniqlanib, u o‘sish differensiatsiyasi omili 15 (GDF-15), urokinaza turidagi plazminogen aktivatorining yuza retseptori (U-PAR), matriks metalloproteinaza-12 (MMP-12), o‘sma nekrozi omili bilan bog‘liq apoptozni keltirib chiqaruvchi ligand retseptori 2 (TRAIL-R2), spondin-1 (SPON1) va follistatin (FS) mavjudligi bilan bog‘liq ekani ko‘rsatildi. Bu exokardiografik kuzatuv orqali aniqlandi. Barcha P qiymatlari 0,02 dan past edi. Natijalar. PIV ning yakuniy tavsiflari jami 901 nafar ishtirokchi orasida yoshning medianasi 70 yil ekanini o‘z ichiga oldi. LSAM da tavsif 685 nafar ishtirokchi orasida yoshning medianasi 78 yil ekanini ko‘rsatdi. PIV da kuzatuv davrida yosh oralig‘i 0,1-10,9 yilni tashkil etib, medianasi 10 yil bo‘ldi, yurak yetishmovchiligi sababli 80 marta kasalxonaga yotqizish qayd etildi, yurak yetishmovchiligi darajasi esa 100 kishiga 0,96 ni tashkil qildi. LSAM da yurak yetishmovchiligi sababli 90 marta kasalxonaga yotqizish bo‘lib, yosh oralig‘i 0,2-10,9 yilni, medianasi 8 yilni tashkil etdi, yurak yetishmovchiligi darajasi esa 100 kishiga 1,83 ni tashkil qildi. PIV da soxta topilmalar darajasi 5% bo‘lib, jins va yoshga tuzatish kiritilgandan so‘ng 29 ta oqsil bilan bog‘liqlik aniqlandi. LSAM da 18 ta oqsilning yurak yetishmovchiligi yuzaga kelishi bilan bog‘liqligi nominal edi. Xulosa. Keksalar orasida o‘tkazilgan ushbu tadqiqotda proteomik profillash orqali oqsillarning fibrinoliz, apoptoz, yallig‘lanish, matriksni qayta shakllantirish va yurak yetishmovchiligidagi ishtirokiga oid bir qancha yangi bog‘liqliklar aniqlandi. Ushbu tadqiqot natijalari asosiy mexanizmlar va klinik qo‘llanilishni o‘rgangan boshqa tadqiqotlarga ham mos keladi.</p>
      </trans-abstract>
      <kwd-group xml:lang="en">
        <kwd>Epidemiology</kwd>
        <kwd>Heart failure</kwd>
        <kwd>Left ventricular dysfunction</kwd>
        <kwd>Risk prediction</kwd>
        <kwd>Proteomics and Biomarkers</kwd>
      </kwd-group>
      <kwd-group xml:lang="ru">
        <kwd>эпидемиология</kwd>
        <kwd>сердечная недостаточность</kwd>
        <kwd>дисфункция левого желудочка</kwd>
        <kwd>прогнозирование риска</kwd>
        <kwd>протеомика и биомаркеры</kwd>
      </kwd-group>
      <kwd-group xml:lang="uz">
        <kwd>Epidemiologiya</kwd>
        <kwd>Yurak yetishmovchiligi</kwd>
        <kwd>Chap qorincha disfunksiyasi</kwd>
        <kwd>Xavfni bashorat qilish</kwd>
        <kwd>Proteomika va biomarkerlar</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <back>
    <ref-list>
      <ref id="r1">
        <label>1</label>
        <mixed-citation>Arterioscler Thromb Vasc Biol 2005;25:2368–2375. Hedstrand H. A study of middle-aged men with particular reference to risk factors for cardiovascular disease. Ups J Med Sci Suppl 1975; 19:1–61.</mixed-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <mixed-citation>Borne Y, Persson M, Melander O, Smith JG, Engstrom G. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. Eur J Heart Fail 2014; 16:377–383.</mixed-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <mixed-citation>Clemitson JR, Dixon RJ, Haines S, Bingham AJ, Patel BR, Hall L, Lo M, Sassard J, Charchar FJ, Samani NJ. Genetic dissection of a blood pressure quantitative trait locus on rat chromosome 1 and gene expression analysis identifies SPON1 as a novel candidate hypertension gene. Circ Res 2007;100: 992–999.</mixed-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <mixed-citation>Echouffo-Tcheugui JB, Greene SJ, Papadimitriou L, Zannad F, Yancy CW, Gheorghiade M, Butler J. Population risk prediction models for incident heart failure: a systematic review. Circ Heart Fail 2015;8:438–447.</mixed-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <mixed-citation>Helske S, Kovanen PT, Lindstedt KA, Lommi J, Turto H, Werkkala K, Kupari M. Increased osteoprotegerin and decreased RANKL associate with the severity of heart failure in patients with aortic stenosis. Circulation 2005; 112: U818–U.</mixed-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <mixed-citation>Hong Y, XieW, Chen CS. Effect of shengmai injection on TRAIL death receptor of patients with congestive heart failure. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005; 25:1092–1095.</mixed-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <mixed-citation>Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study.</mixed-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <mixed-citation>Lind L, Ärnlöv J, Lindahl B, Siegbahn A, Sundström J, Ingelsson E. Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. Atherosclerosis 2015;242:205–210.</mixed-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <mixed-citation>Mi H, Muruganujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc 2013;8:1551–1566.</mixed-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <mixed-citation>McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998;19 Suppl P: P9–P16.</mixed-citation>
      </ref>
      <ref id="r11">
        <label>11</label>
        <mixed-citation>Willingale R, Jones DJ, Lamb JH, Quinn P, Farmer PB, Ng LL. Searching for biomarkers of heart failure in the mass spectra of blood plasma. Proteomics 2006; 6:5903–5914.</mixed-citation>
      </ref>
      <ref id="r12">
        <label>12</label>
        <mixed-citation>Aslam, I., Asadullah, R. N. A., Akhlaq, F., Ali, A., &amp; Fatima, A. (2023). Diabetic Disease and its 2-4 Fold Mortality Rate, Patients Getting Standard Therapy in the Modern ERA of CVD Risk Reduction. Pakistan Journal of Medical &amp; Health Sciences, 17(01), 420-420.</mixed-citation>
      </ref>
      <ref id="r13">
        <label>13</label>
        <mixed-citation>Rajabboevna, A. R., &amp; Yangiboyevna, N. S. (2023). EPILEPSIYA BILAN OG&apos;RIGAN BEMORLARDA TOPAMAX DORI VOSITASINING KLINIK VA FARMAKOEKONOMIK ASPEKTLARINING SAMARADORLIGINI BAHOLASH. Research Focus International Scientific Journal, 2(5), 198-202.</mixed-citation>
      </ref>
      <ref id="r14">
        <label>14</label>
        <mixed-citation>Jiyanboyevich, Y. S., Aslam, I., Ravshanovna, M. U., Azamatovna, F. G., &amp; Murodovna, J. D. (2021). Ventricular Arrhythmias With Congenital Heart Disease Causing Sudden Death. NVEO-NATURAL VOLATILES &amp; ESSENTIAL OILS Journal| NVEO, 2055-2063.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
